{"id":392286,"date":"2020-12-02T20:03:17","date_gmt":"2020-12-03T01:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=392286"},"modified":"2020-12-02T20:03:17","modified_gmt":"2020-12-03T01:03:17","slug":"bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/","title":{"rendered":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm"},"content":{"rendered":"
\n

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Neovasc, Inc. (NASDAQ: NVCN), and Interface, Inc. (NASDAQ: TILE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.<\/p>\n

\n Raytheon Technologies Corporation (NYSE: RTX) <\/strong>\n <\/p>\n

Class Period: February 10, 2016 to October 27, 2020<\/p>\n

Lead Plaintiff Deadline: December 29, 2020<\/p>\n

On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter ended September 30, 2020 (the \u201c3Q20 Report\u201d). The 3Q20 Report announced the DOJ Investigation, stating in pertinent part: \u201cOn October 8, 2020, the Company received a criminal subpoena from the DOJ seeking information and documents in connection with an investigation relating to financial accounting, internal controls over financial reporting, and cost reporting regarding Raytheon Company\u2019s Missiles & Defense business since 2009.\u201d<\/p>\n

On this news, the price of Raytheon shares fell $4.19 per share, or 7%, to close at $52.34 per share on October 28, 2020, on unusually heavy trading volume, damaging investors.<\/p>\n

The complaint, filed on October 30, 2020, alleges that throughout the Class Period defendants made false and\/or misleading statements and\/or failed to disclose that: (1) Raytheon had inadequate disclosure controls and procedures and internal control over financial reporting; (2) Raytheon had faulty financial accounting; (3) as a result, Raytheon misreported its costs regarding Raytheon’s Missiles & Defense business since 2009; (4) as a result of the foregoing, Raytheon was at risk of increased scrutiny from the government; (5) as a result of the foregoing, Raytheon would face a criminal investigation by the U.S. Department of Justice (\u201cDOJ\u201d); and (6) as a result, defendants’ public statements were materially false and\/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

For more information on the Raytheon class action go to: https:\/\/bespc.com\/cases\/RTX<\/a><\/p>\n

\n Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) <\/strong>\n <\/p>\n

Class Period: September 28, 2019 to October 7, 2020<\/p>\n

Lead Plaintiff Deadline: January 4, 2021<\/p>\n

Intercept\u2019s lead product candidate is Ocaliva (obeticholic acid (\u201cOCA\u201d)), a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (\u201cPBC\u201d), a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults. The Company is also developing OCA for various other indications, including nonalcoholic steatohepatitis (\u201cNASH\u201d).<\/p>\n

On May 22, 2020, Intercept reported that the FDA \u201chas notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company\u2019s [NDA] for [OCA] for the treatment of liver fibrosis due to [NASH] has been postponed\u201d to \u201caccommodate the review of additional data requested by the FDA that the company intends to submit within the next week.\u201d<\/p>\n

On this news, Intercept\u2019s stock price fell $11.18 per share, or 12.19%, to close at $80.51 per share on May 22, 2020.<\/p>\n

On June 29, 2020, Intercept issued a press release announcing that the FDA had issued a Complete Response Letter (\u201cCRL\u201d) rejecting the Company\u2019s NDA for Ocaliva for the treatment of liver fibrosis due to NASH.<\/p>\n

On this news, Intercept\u2019s stock price fell $30.79 per share, or 39.73%, to close at $46.70 per share on June 29, 2020.<\/p>\n

Then, on October 8, 2020, news outlets reported that Intercept was \u201cfacing an investigation from the [FDA] over the potential risk of liver injury in patients taking Ocaliva, [Intercept\u2019s] treatment for primary biliary cholangitis, a rare, chronic liver disease.\u201d<\/p>\n

On this news, Intercept\u2019s stock price fell $3.30 per share, or 8.05%, to close at $37.69 per share on October 8, 2020.<\/p>\n

The complaint, filed on November 5, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company\u2019s business, operational and compliance policies. Specifically defendants made false and\/or misleading statements and\/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva\u2019s use in treating PBC; (ii) the foregoing increased the likelihood of an FDA investigation into Ocaliva\u2019s development, thereby jeopardizing Ocaliva\u2019s continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA\u2019s efficacy in treating NASH were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company\u2019s NDA for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

For more information on the Intercept class action go to: https:\/\/bespc.com\/cases\/ICPT-2<\/a><\/p>\n

\n Neovasc, Inc. (NASDAQ: NVCN) <\/strong>\n <\/p>\n

Class Period: October 10, 2018 to October 27, 2020<\/p>\n

Lead Plaintiff Deadline: January 4, 2021<\/p>\n

Neovasc is a specialty medical device company that develops, manufactures and markets products for cardiovascular diseases, including the Tiara technology and the Reducer. The Company\u2019s Reducer is a medical device that treats refractory angina by altering blood flow in the heart\u2019s circulatory system.<\/p>\n

On October 28, 2020, before the market opened, the Company announced that an FDA advisory panel voted overwhelmingly against the safety and effectiveness of the Reducer. The panel noted concerns with the Company\u2019s clinical data, including \u201cthat the lack of blinding assessment made the primary endpoint difficult to interpret.\u201d As a result, the panel reached a consensus \u201cthat additional premarket randomized clinical data was necessary.\u201d<\/p>\n

On this news, the Company\u2019s share price fell $0.77, or 42%, to close at $1.06 per share on October 28, 2020.<\/p>\n

The complaint, filed on November 5, 2020, alleges that throughout the Class Period defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc\u2019s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company\u2019s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n

For more information on the Neovasc class action go to: https:\/\/bespc.com\/cases\/NVCN<\/a><\/p>\n

\n Interface, Inc. (NASDAQ: TILE) <\/strong>\n <\/p>\n

Class Period: March 2, 2018 to September 28, 2020<\/p>\n

Lead Plaintiff Deadline: January 11, 2021<\/p>\n

On\u00a0April 24, 2019, Defendants filed a current report on Form 8-K with the SEC, disclosing,\u00a0inter alia<\/em>, that Interface \u201creceived a letter in\u00a0November 2017\u00a0from the [SEC] requesting that the Company voluntarily provide information and documents in connection with an investigation into the Company\u2019s historical quarterly [EPS] calculations and rounding practices during the period 2014-2017\u201d; that \u201c[t]he Company subsequently received subpoenas from the SEC in\u00a0February 2018,\u00a0July 2018\u00a0and\u00a0April 2019\u00a0requesting additional documents and information\u201d; and that \u201c[i]n the fourth quarter of 2018, the Company conducted at the SEC’s request an internal investigation into these and other related issues for seven quarters in 2015, 2016 and 2017.\u201d<\/p>\n

On this news, Interface\u2019s stock price fell\u00a0$1.43\u00a0per share, or 8.37%, to close at\u00a0$15.66\u00a0per share on\u00a0April 25, 2019.<\/p>\n

Then, on\u00a0September 28, 2020, the SEC announced the conclusion of its investigation into Interface’s historical quarterly EPS calculations and rounding practices. Interface agreed to pay a\u00a0$5 million\u00a0fine to resolve the matter and was ordered to cease and desist from violating the federal securities laws. In the SEC\u2019s enforcement order issued that same day, the SEC also disclosed how,\u00a0inter alia<\/em>, \u201cInterface employees caused Interface to produce documents in response to Commission investigative requests that were suggestive of contemporaneous support for journal entries that, in truth, did not exist at the time the entries were recorded,\u201d and had modified certain documents after the SEC\u2019s investigation began.<\/p>\n

On this news, Interface\u2019s stock price fell\u00a0$0.20\u00a0per share, or 3.13%, over the following two trading sessions to close at\u00a0$6.18\u00a0per share on\u00a0September 29, 2020.<\/p>\n

The complaint, filed on November 12, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company\u2019s business, operational and compliance policies. Specifically, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) Interface had inadequate disclosure controls and procedures and internal control over financial reporting; (ii) consequently, Interface,\u00a0inter alia<\/em>, reported artificially inflated income and earnings per share (\u201cEPS\u201d) in 2015 and 2016; (iii) Interface and certain of its employees were under investigation by the Securities and Exchange Commission (\u201cSEC\u201d) with respect to the foregoing issues since at least as early as\u00a0November 2017, had impeded the SEC\u2019s investigation, and downplayed the true scope of the Company\u2019s wrongdoing and liability with respect to the SEC investigation; and (iv) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

For more information on the Interface class action go to: https:\/\/bespc.com\/cases\/TILE<\/a><\/p>\n

\n About <\/strong>
\n Bragar<\/strong>
\n Eagel<\/strong>
\n & Squire, P.C.:<\/strong>
\n
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com<\/u><\/a>. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n Contact Information:<\/strong>
\n
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com<\/u><\/a>
www.bespc.com<\/a><\/u>\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Neovasc, Inc. (NASDAQ: NVCN), and Interface, Inc. (NASDAQ: TILE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Raytheon Technologies Corporation (NYSE: RTX) Class Period: February 10, 2016 to October 27, 2020 Lead Plaintiff Deadline: December 29, 2020 On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter … <\/p>\n

Continue reading “Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-392286","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Neovasc, Inc. (NASDAQ: NVCN), and Interface, Inc. (NASDAQ: TILE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Raytheon Technologies Corporation (NYSE: RTX) Class Period: February 10, 2016 to October 27, 2020 Lead Plaintiff Deadline: December 29, 2020 On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter … Continue reading "Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-03T01:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm\",\"datePublished\":\"2020-12-03T01:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/\"},\"wordCount\":1652,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/\",\"name\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=\",\"datePublished\":\"2020-12-03T01:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/","og_locale":"en_US","og_type":"article","og_title":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Raytheon Technologies Corporation (NYSE: RTX), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Neovasc, Inc. (NASDAQ: NVCN), and Interface, Inc. (NASDAQ: TILE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Raytheon Technologies Corporation (NYSE: RTX) Class Period: February 10, 2016 to October 27, 2020 Lead Plaintiff Deadline: December 29, 2020 On October 27, 2020, after market hours, Raytheon filed its quarterly report on Form 10-Q with the SEC for the quarter … Continue reading \"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-03T01:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm","datePublished":"2020-12-03T01:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/"},"wordCount":1652,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/","name":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=","datePublished":"2020-12-03T01:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NTgxNyMzODUzMzUxIzIxMDAzOTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-raytheon-intercept-pharmaceuticals-neovasc-and-interface-and-encourages-investors-to-contact-the\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Raytheon, Intercept Pharmaceuticals, Neovasc and Interface and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=392286"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/392286\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=392286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=392286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=392286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}